PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Personalized vaccine for most lethal type of brain tumor shows promise

2013-12-16
(Press-News.org) Contact information: Sheila Galloro
sgalloro@nmh.org
312-926-0735
Northwestern Memorial Hospital
Personalized vaccine for most lethal type of brain tumor shows promise CHICAGO – Patients with recurrent glioblastoma multiforme (GBM) treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine that was recently published in the journal Neuro-Oncology and accompanied by an editorial highlighting the importance of the trial.

A GBM took the life of former Senator Edward Kennedy in 2009. The most aggressive form of primary brain tumor, GBM tumors are often resistant to standard therapies and median survival is approximately three to nine months for a recurrent tumor.

"We are talking about fast-growing tumors that invade normal brain tissue and are very difficult to treat," said Orin Bloch, MD, a neurosurgeon at Northwestern Memorial Hospital and lead author of the study. "These tumors occur in up to 23,000 Americans annually, and are typically treated with surgical resection of the tumor followed by chemotherapy and radiation treatment."

This phase 2 trial enrolled 41 adult patients with recurrent tumors between 2007 and 2011. Each patient received an average of six doses of the HSPPC-96 vaccine. Following treatment, 90 percent of patients were alive at six months and 30 percent were alive after one year. Further study will be needed to see if this vaccine could potentially be approved to treat recurrent brain tumors. Currently there are only a few approved therapeutic cancer vaccines, none of which are approved for the treatment of GBM.

While new findings continue to extend the lives of patients with glioblastoma, for the moment, it remains one of the most dreaded diagnoses because despite treatment, GBMs almost always come back, said Bloch.

"The grim prognosis is exactly why new research is important," said Bloch, who is an assistant professor of neurological surgery at the Northwestern Feinberg School of Medicine. "GBMs have been around for a long time, and still outcomes are poor. With studies such as this one, I believe we can change that."

The vaccine, HSPPC-96, is produced individually for each patient using that patient's own resected tumor tissue. Following the patient's surgery, the tumor is sent to the vaccine production facility at Agenus Inc., where the HSPPC-96 vaccine is created. The vaccine is unique to the individual participant and is engineered to trigger an immune system response to kill tumor cells that may remain following surgery.

Northwestern Medicine researchers are currently conducting the next phase of this research, a randomized phase II trial which will investigate if the HSPPC-96 vaccine is safe and more effective when given with Avastin (bevacizumab). Avastin is a drug that is known to shrink brain tumors and is a standard therapy for recurrent GBM.

"When it comes to brain tumor research, I picture our Northwestern Medicine team climbing a mountain and with every new discovery that shows the potential to prolong survival, we are establishing a new base camp," said Andrew Parsa, MD, PhD, corresponding author of the study and chair of neurological surgery at Northwestern Memorial and the Michael J. Marchese Professor and chair of the department of neurological surgery at the Feinberg School. "Someday, thanks to studies like this one, we'll get to the top of the mountain and convert this particular cancer into a chronic disease – something that patients can live with, controlled by medication."

INFORMATION:

The study, which is chaired by Parsa, is the largest randomized brain tumor vaccine trial ever funded by the National Cancer Institute (NCI). The study is sponsored by the Alliance for Clinical Trials in Oncology (ALLIANCE), a cooperative group of the NCI.

Bloch and Parsa are members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and part of the Northwestern Brain Tumor Institute.

To learn more about the clinical trial, call 312-695-2047 or email kskirnyk@nmff.org. Enrollment criteria can be viewed on the Lurie Cancer Center website.

END



ELSE PRESS RELEASES FROM THIS DATE:

Gene variant exacerbates inflammatory arthritis in mice

2013-12-16
Gene variant exacerbates inflammatory arthritis in mice Study reveals new mechanism for arthritis progression (SALT LAKE CITY)—University of Utah researchers have discovered a naturally occurring genetic variation in mice that predisposes carriers toward ...

Do degrading TV portrayals of women cause gender harassment?

2013-12-16
Do degrading TV portrayals of women cause gender harassment? A new study in Psychology of Women Quarterly considers whether objectifying women in television and harassment are causally linked. Researchers Silvia Galdi, Anne Maass, and Mara Cadinu designed two ...

5 effective parenting programs to reduce problem behaviors in children

2013-12-16
5 effective parenting programs to reduce problem behaviors in children All parents want what's best for their children. But not every parent knows how to provide their child with the tools to be successful, or how to help them avoid the biggest adolescent behavior ...

Linking social science and ecology to solve the world's environmental problems

2013-12-16
Linking social science and ecology to solve the world's environmental problems Researchers from the ARC Centre of Excellence for Coral Reef Studies (CoECRS) at James Cook University are engaging social science ...

NTU scientists discover potential vaccine for malaria

2013-12-16
NTU scientists discover potential vaccine for malaria Scientists from Singapore's Nanyang Technological University (NTU) have discovered a key process during the invasion of the blood cell by the Malaria parasite, and more importantly, found a way to block ...

Alzheimer substance may be the nanomaterial of tomorrow

2013-12-16
Alzheimer substance may be the nanomaterial of tomorrow Amyloid protein causes diseases like Alzheimer's, Parkinson's and Creutzfeldt-Jakob disease. But amyloid also carries unique characteristics that may lead to the development of new composite ...

Nanoparticles and their orbital positions

2013-12-16
Nanoparticles and their orbital positions Physicists have developed a "planet-satellite model" to precisely connect and arrange nanoparticles in three-dimensional structures. Inspired by the photosystems of plants and algae, these artificial nanoassemblies ...

VTT: Biorefinery business could put the South Australian forest industry back on the growth track

2013-12-16
VTT: Biorefinery business could put the South Australian forest industry back on the growth track VTT Technical Research Centre of Finland, at the request of the South Australian State Government, studied the condition of the forest sector ...

Brain waves encode information as time signals

2013-12-16
Brain waves encode information as time signals How information is processed and encoded in the brain is a central question in neuroscience, as it is essential for high cognitive function such as learning and memory. Theta-gamma ...

Nanofriction on the tip of the microscope

2013-12-16
Nanofriction on the tip of the microscope A new research paper from SISSA published in Nature Materials Atomic force microscopes are able to reproduce spectacular images, at the scale of single atoms. This is made possible by the ...

LAST 30 PRESS RELEASES:

MD Anderson Research Highlights for July 16, 2025

Interbreeding with Neanderthals may be responsible for modern-day brain condition, SFU study finds

Tiny crystals provide insight to massive 2006 Augustine Volcano eruption

Six-month follow-up results announced from a first-of-its-kind robotic-assisted cerebral aneurysm embolization study

Why some elephants take more risks around people than others

Hope in sight for autosomal dominant optic atrophy (ADOA)

Snacking on avocado before bed may be linked to health impacts the next morning in adults with prediabetes

‘Fiery’ cell death during bladder cancer treatment may trigger chemo resistance by fueling cancer stem cells

How a tiny gene ensures the survival of male birds

New insights into ovarian cancer: why whole-genome doubling may hold the key to future HGSOC treatment strategies

Battery sharing could cut energy costs for communities

Expanded research tool to crack the code on Parkinson’s, the fastest-growing neurodegenerative disease

Can AI detect hidden heart disease?

Simple rules govern soil microbiome responses to environmental change

Researchers track the willingness of gun owners to temporarily store guns outside their homes

Living near St. Louis-area Coldwater Creek during childhood linked with higher risk of cancer from radiation

Prevalence of extremely severe obesity and metabolic dysfunction among US children and adolescents

Estimated burden of influenza and direct and indirect benefits of influenza vaccination

Projected health system and economic impacts of 2025 Medicaid policy proposals

New tech for imaging brain waves could advance disease research, AI

Immigrants in U.S. earn 10.6% less than native-born workers, but biggest driver is job access, not wage discrimination 

New peer-reviewed study reveals severe health and economic consequences of 2025 Medicaid policy changes

Faster, smarter, more open: a new way to accelerate AI models

What does it cost an animal to fight?

Discovery could battle Alzheimer’s by boosting blood flow to brain

New antibody selectively targets immune cells that suppress anti-tumor responses

OHSU scientists develop tool that improves tissue cancer analysis

The 2025 World Cultural Council’s award winner is announced

Stephenson Global Scholar Grants Program awards $5.3 million to drive breakthroughs in pancreatic cancer research

A statement from the Global Virus Network (GVN) on the rapidly escalating measles crisis in the U.S. and worldwide

[Press-News.org] Personalized vaccine for most lethal type of brain tumor shows promise